• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Drug Products
  • All Drug Products
  • A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

Disease
lung cancer
Drug Name
IRESSA
Generic Name
gefitinib
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
IV
Start Date
Aug 1, 2009
Study Name
1839IL/0052 SubStudy
Study Id
1839IL/0052 SubStudy
ClinicalTrials.gov ID
NCT01000740
Recruiting Status
Open
Protocol Status
Not Available
Report
Aug 31, 2010
  • 1839IL/0052.pdf (121 KB)

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013